This French Biotech Delivers Drugs to Exactly Where They Need to be

This week we’re visiting BioCellChallenge, based in Signes, France, which finds ways to deliver antibodies and peptides into cells, helping them to show their true therapeutic potential.

Mission: In 2009, BioCellChallenge began searching for ways to deliver drugs into cells, which can be a problem for new therapies. The biotech has developed ImmunoCellin that, without damaging the antibody, integrates lipid structures into the protein so that it can be delivered directly into a target cell. This means that antibodies, which have huge therapeutic potential, can now reach a range of new targets. The company hopes to use its technology for therapeutic peptides, which have so far been used sparingly in pharmaceuticals due to their difficulty in crossing cell membranes.

Comment: With over 90% of the deregulated targets that lead to the disease found inside cells, the ability to effectively deliver antibodies and therapeutic peptides into cells could be ground-breaking. Biotechs like Complix and Ablynx are developing Alphabodies and nanobodies, respectively, which can freely pass across membranes. However, BioCellChallenge’s technology could breath new life into existing antibody and peptide therapies.


Image – Grisha Bruev / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.